Biolojic Design, founded by Yanay Ofran, is pioneering AI-driven programmable antibodies for cancer and autoimmune diseases. Their platform produced AU-007, the first computationally designed antibody to enter human trials, now in Phase II. Biolojic has partnered with Teva, Eli Lilly, and Merck KGaA to advance these innovative therapies.  

The Pharma Letter Podcast — Episode 29 — How can we use AI to program antibodies? | Biotechnology | The Pharmaletter | The Pharmaletter

The Pharma Letter Podcast — Episode 29 — How can we use AI to program antibodies?

column-header-date-desktop-only-1

column-header-logo-1

column-header-secondary-menu-desktop-only-1

row-header-1

row-header-and-main-menu-1

row-menu-container-1

code-sticky-header-1

row-header-background-1

banner-leaderboard

row-leaderboard

row-leaderboard-banner-bg-container

breadcrumb

row-breadcrumb

datasummary-page-title

row-title-row

row-row-category-date-container

row-category-date

column-main

column-sidebar

row-main-section

card-more-features-in-category

row-other-related

code-banner-spacer-3

banner-billboard-bottom

row-billboard-bottom

row-page

footer-first-column-2

footer-second-column-2

footer-third-column-2

row-footer-2

row-footer-container-2

textblock-copyright

row-copyright

backtotop-1

gtm-user-all-block

structured-data-component-header-auto

The Pharma Letter Podcast — Episode 29 — How can we use AI to program antibodies?

More on this story...

Companies featured in this story

Today's issue

Company Spotlight

More Features in Biotechnology